Imricor Medical Systems (ASX:IMR) said it expects a "steady string" of US Food and Drug 510(k) product submissions and approvals through the remainder of the year, according to a Monday filing with the Australian bourse.
During the June quarter, the company's cash balance fell to $50.3 million from $53.9 million in the March quarter.
Shares of the company fell past 3% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.